ReviewBlood advances2025
Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels.
Review in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Rethinking secondary immunodeficiency: a cross-domain pathway framework for risk stratification.Frontiers in immunology · 2026Pooled it
- Infection risk associated with talquetamab in relapsed/refractory multiple myeloma: a systematic review with meta-analysis of talquetamab monotherapy and descriptive analysis of combination therapy.Frontiers in immunology · 2026Pooled it
- Patient preferences for treatment‑free intervals in multiple myeloma: mixed‑methods insights on monitoring trade‑offs and supportive care improvements.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Estimating the Healthcare Cost of Infection-Related Hospitalisations in Multiple Myeloma.PharmacoEconomics · 2026Article
- REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials.Haematologica · 2026Observational
- GPRC5D-targeting bispecific and trispecific antibodies in multiple myeloma: Current evidence and emerging strategies.Cancer · 2026Review
- Article
- Mitigating Teclistamab Toxicity: Prophylactic Tocilizumab and Timing of Immunoglobulin Replacement Therapy in a Nationwide Cohort.American journal of hematology · 2026Article
- Targeting BCMA in patients with relapsed/refractory multiple myeloma in 1 to 3 prior lines of therapy.Blood advances · 2026Review
- Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma.Cancer · 2026Article
- Mechanistic modeling of FcRn-dependent IgG drug interactions: Clinical applications and dosing implications.Journal of pharmacokinetics and pharmacodynamics · 2026Article
- Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis.Blood advances · 2026Article
- Article
- Immunoglobulin after bispecifics requires randomized trial.Blood advances · 2026Article
- Vaccination should not be forgotten in patients receiving immunoglobulin replacement therapy.Blood advances · 2026Article
- Vaccination during bispecific antibody treatment for myeloma.Blood advances · 2026Article
- Bispecific Antibodies: Strategies Available to Optimize Their Safe Delivery in Patients with Multiple Myeloma.Antibodies (Basel, Switzerland) · 2026Review
- Current positioning and future development of belantamab mafodotin and other antibody-drug conjugates to treat multiple myeloma.Frontiers in oncology · 2026Review
- Practical recommendations for infectious prophylaxis and vaccination in multiple myeloma patients.Frontiers in medicine · 2026Review
- Teclistamab for Relapsed or Refractory Multiple Myeloma: A Review of Efficacy, Safety, Resistance Mechanisms and Future Directions.Biologics : targets & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractBispecific antibodies (bsAbs), such as teclistamab, elranatamab, linvoseltamab, and talquetamab, have impressive efficacy in multiple myeloma (MM) but come with substantial infectious risks that do not dissipate over time. Immunoglobulin replacement therapy (IgRT), which includes IV and subcutaneous (SC) immunoglobulins, may lower these risks. In this viewpoint, we contrast primary IgRT prophylaxis (initiation regardless of IgG levels) with preemptive IgRT treatment (initiation only once IgG levels fall below a certain threshold) in this setting. We make evidence-based arguments for primary prophylaxis as a safer and simpler approach than preemptive IgG-guided IgRT. We also discuss strategies to improve the cost-effectiveness of IV and SC immunoglobulins across the world. Given the overwhelmingly favorable benefit-risk profile of IgRT, coupled with the limitations inherent to IgG measurements in MM, withholding IgRT access based on arbitrary IgG thresholds is neither scientifically sound nor clinically appropriate for patients with MM who are receiving bsAb therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.